Welcome to our dedicated page for Exicure news (Ticker: XCUR), a resource for investors and traders seeking the latest updates and insights on Exicure stock.
Exicure, Inc. (Nasdaq: XCUR) is a clinical-stage biotechnology company developing therapies for hematologic diseases, with a lead focus on the small molecule CXCR4 antagonist burixafor (GPC-100). The Exicure news feed highlights how the company advances this program across multiple indications and how its financial and corporate decisions affect the XCUR stock story.
Readers can follow updates on Exicure’s clinical trials, including an open-label, multicenter Phase 2 study of burixafor in combination with propranolol and G-CSF in patients with multiple myeloma undergoing autologous hematopoietic cell or stem cell transplantation. Company announcements describe topline and interim results, rates of successful CD34+ cell mobilization, engraftment outcomes for participants who proceed to transplant, and safety observations for the burixafor-based regimen.
News items also cover pipeline expansion plans, where Exicure discusses potential use of burixafor in sickle cell disease, rare diseases requiring autologous transplant, cell and gene therapy settings, and as a potential chemosensitizing agent in acute myeloid leukemia (AML). These releases outline how mobilizing hematopoietic or malignant cells from the bone marrow niche into peripheral blood could support transplant procedures or enhance chemotherapy effectiveness.
In addition, the XCUR news stream includes financial results and going concern disclosures, detailing quarterly cash balances, research and development and general and administrative expenses, and management’s assessment that additional financing is needed to fund operations and strategic alternatives. Corporate governance and listing-related developments, such as Nasdaq compliance notices, annual meeting information, and board composition changes, are also reported.
Investors and followers of Exicure can use this page to monitor clinical data presentations, strategic updates related to the acquisition of GPCR Therapeutics USA Inc., and regulatory or capital markets filings that shape the company’s hematology-focused trajectory. Bookmark this feed to review new press releases and regulatory-linked news as they are published.
Exicure, Inc. (NASDAQ: XCUR), a leader in gene regulatory and immunotherapeutic drugs, has announced its participation in two scientific conferences in September 2021. These events include TIDES USA 2021, where Exicure will present research on the biodistribution of Spherical Nucleic Acids (SNA) in rats, and the 17th Annual Meeting of the Oligonucleotide Therapeutics Society, focusing on SNA targeting FXN for treating Friedreich's Ataxia. Posters will be available on Exicure's website after the events.
Exicure is based in Chicago and Cambridge, developing therapeutics for various genetic disorders.
Exicure, Inc. (NASDAQ: XCUR), a biotechnology company, announced its participation in key investor conferences for September 2021. The events include Citi’s 16th Annual Biopharma Conference from September 8-10, the H.C. Wainwright 23rd Annual Global Investment Conference with a presentation on September 13 at 7:00 AM ET, and the Baird Global Healthcare Conference on September 14 at 9:40 AM ET. The company is focused on developing therapeutics using its Spherical Nucleic Acid technology, with candidates targeting Friedreich’s ataxia and advanced solid tumors.
Exicure, Inc. (NASDAQ:XCUR) reported its financial results for Q2 2021, highlighting collaborations and advancements in its neurology pipeline. A $20 million upfront payment from Ipsen for Huntington’s disease and Angelman syndrome collaboration reinforces its financial stability, with potential for up to $1 billion in milestones. Research & Development expenses rose to $10.8 million, contributing to a net loss of $14.3 million. Despite increased losses, the company maintains sufficient liquidity, expecting to fund operations for at least 12 months due to existing cash and new partnership inflows.
Exicure, Inc. (NASDAQ: XCUR) has released an update on the Phase 1b/2 clinical trial of cavrotolimod (AST-008), targeting advanced solid tumors. Interim data shows that 26 patients have been dosed in the Phase 2 stage, with 17 evaluable patients. Notably, one patient with Merkel cell carcinoma (MCC) achieved a complete response, allowing for continued enrollment in the study. The overall response rate in evaluable MCC patients was 21%. The trial has seen a majority of treatment-related adverse events classified as mild, with two serious cases reported.
Exicure, a leader in gene regulatory therapeutics, has announced that CEO David Giljohann will present at the BTIG Virtual Biotechnology Conference on August 9, 2021, at 2:30 PM ET. During the event, Exicure will also host one-on-one investor meetings. The company is known for its Spherical Nucleic Acid technology and is developing treatments for various diseases, including neurology and immuno-oncology. Notably, Exicure is working on XCUR-FXN for Friedreich’s ataxia and cavrotolimod (AST-008) for advanced solid tumors.
Ipsen and Exicure Inc. have entered a collaboration to develop novel Spherical Nucleic Acids (SNAs) targeting Huntington’s disease and Angelman syndrome. Ipsen will pay Exicure $20 million upfront, with potential for up to $1 billion in milestone payments and royalties. SNAs are expected to enhance drug delivery to hard-to-reach areas like the brain. Both diseases currently lack approved disease-modifying therapies, presenting a significant market opportunity. The partnership aims to leverage Ipsen's expertise in neuroscience and Exicure's innovative delivery technology to address these unmet medical needs.
Exicure, Inc. (NASDAQ: XCUR) will host a virtual R&D Day on July 15, 2021, highlighting its neuroscience pipeline, particularly XCUR-FXN for Friedreich's Ataxia (FA). This program targets the disease's molecular cause and is on track for IND filing in late Q4 2021. The event will also cover advancements in therapies for SCN9A-related neuropathic pain and CLN3 Batten Disease. CEO Dr. David Giljohann emphasizes the potential of their SNA platform to address neurological disorders with promising data that may benefit patients.
Exicure, Inc. (NASDAQ: XCUR) announced that CEO David Giljohann will present at the Ladenburg Thalmann 2021 Healthcare Conference on July 13, 2021, from 1:00-1:25 PM in Track One. The panel discussion will be webcast, with replays available for 30 days on Exicure's website. The company focuses on gene regulatory and immunotherapeutic drugs utilizing its proprietary Spherical Nucleic Acid (SNA™) technology, aimed at treating neurological, immuno-oncologic, and inflammatory diseases. Exicure is developing XCUR-FXN for Friedreich’s ataxia and cavrotolimod for advanced solid tumors.
Exicure, Inc. (NASDAQ: XCUR) has announced CEO David Giljohann's participation in two upcoming conferences. The BIO Digital 2021 conference will feature a corporate update presentation on June 10, 2021, available for on-demand viewing. The BMO Biopharma Day will include a rare disease panel on June 22, 2021, streamed live at 10:30 AM ET. Exicure focuses on developing innovative therapeutics leveraging its Spherical Nucleic Acid technology, targeting conditions such as Friedreich’s ataxia and advanced solid tumors.
Exicure, Inc. (NASDAQ: XCUR) has appointed Brian C. Bock as its new Chief Financial Officer, effective immediately. Bock brings over 20 years of experience in life science investment banking and healthcare strategy, previously serving as Managing Director at Lincoln International. His expertise is expected to enhance Exicure’s business strategy and valuation. The company granted Bock an inducement stock option for 600,000 shares at an exercise price of $1.54, vesting over four years. Exicure focuses on developing therapies using its proprietary Spherical Nucleic Acid technology for various diseases.